Citations

Clear

9383 citation(s) found for "Thomas, PS".

Multi‐Institutional Study of ALK ‐Positive Large B‐Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies
Atallah‐Yunes, Suheil Albert , Nze, Chijioke , King, Rebecca L. , Alderuccio, Juan Pablo , Watkins, Marcus P. , Easwar, Neela, Yamshon, Samuel , Ravindra, Aditya, Farooq, Umar , Rojas-Neira, Estela, Ayers, Amy , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Flowers, Christopher R. , Easton, Neil , Nze, Chijioke C , Rees, Matthew James , Alderuccio, Juan Pablo , Watkins, Marcus , Yamshon, Samuel , Rosenthal, Allison , Habermann, Thomas , Witzig, T.E. , Ansell, Stephen M , Wang, Yucai , Easton, Neela , Atallah-Yunes, Albert , Rees, Matthew J. , Kahl, Brad S. , Ravindra, Aditya , Farooq, Umar, Muñoz, Javier , Moustafa, Muhamad Alhaj , Habermann, Thomas M. , Witzig, Thomas E. , Koff, Jean L. , Wang, Yucai

Mayo Clinic

American Journal of Hematology | September 3, 2025 | Volume: 100 | Issue: 12 | Pages: 2185-2194

10.1002/ajh.70058 | PMID 40899786 Get It

ABSTRACT Anaplastic lymphoma kinase‐positive large B‐cell lymphoma (ALK+ LBCL) is a rare, aggressive subtype of diffuse large B‐cell lymphoma with poor outcomes using standard chemotherapy. In this multi‐institutional retrospective study, we analyzed 39 cases of ALK+ LBCL identified at six US academic centers from 2002 to 2024, with treatment including conventional cytotoxic regimens in frontline and biologically informed and nonchemotherapy‐based strategies in the relapsed setting. Ninety‐two percent of patients received frontline anthracycline‐based chemotherapy; 43% received intensified regimens, and 15% underwent upfront autologous stem cell transplantation (ASCT). Despite these approaches, outcomes remained poor. At a median follow‐up of 5.4 years, median event‐free survival (EFS) was 0.6 years (95% CI, 0.4–0.9), and median overall survival (OS) was 1.5 years (95% CI, 1.3–NR). One‐ and five‐year EFS rates were 28% and 17%, while corresponding OS rates were 72% and 42%, respectively. Advanced stage and high IPI scores were associated with inferior outcomes. Twelve patients received ALK inhibitors, with alectinib showing more durable responses than crizotinib. Lenalidomide and immune checkpoint inhibitors also demonstrated activity, including durable complete responses. Five patients underwent allogeneic stem cell transplantation, with three achieving sustained remission. In conclusion, our findings highlight the limited benefit of chemotherapy, even when intensified or followed by ASCT, and support the integration of biologically targeted therapies, which may have contributed to improved OS in our cohort compared to historical outcomes. Prospective, collaborative studies are needed to better understand disease biology and define optimal use of modern therapies in this rare lymphoma.
The Association Between Patient-Reported Social Risks and the HOUSES Index: A Rural-Urban Comparison
Sosso, Jessica , Wi, Chung‐Il , Jegen, Dominika , Matthews, Marc R. , Maxson, Julie, Bernard, Matthew , Foss, Randy , Hidaka, Brandon H. , Passmore, Rachael , Garrison, Gregory M. , Sosso, Jessica L , Wi, Chung-Ii , Jegen, Dominika A , Matthews, Marc, Stacey, Stephen K , Foss, Randy , Hidaka, Brandon , Passmore, Rachael , Garrison, Gregory M , Thacher, Thomas D , Matthews, Marc R , Fischer, Karen M., Thacher, Tom D.

Mayo Clinic

Journal of Primary Care & Community Health | September 2, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251369673 | PMID 40891802 Get It

Introduction/Objectives: Little is known about the prevalence of patient-reported social risk factors and the use of the HOUSES Index, a simple, reliable method of assessing socioeconomic status (SES) based on publicly available housing data, in a predominantly rural, primary care population. Methods: We conducted a cross-sectional analysis of adult patients paneled to family medicine clinicians in a US Midwest health system as of December 31, 2022. Patients’ listed address determined HOUSES Index as quartile rank (Q1 lowest SES) and rural/urban status. Social risk data including housing, food, transportation, finances, and violence were collected from health record questionnaires. A mixed effect model was used to assess associations between social risk, HOUSES Index, and rurality. Results: Of the 352 355 patients included, rural patients were more likely than urban patients to report all social risk factors and had lower SES as measured by HOUSES quartiles. In the mixed effects analysis, HOUSES quartile was independently predictive of reporting an at-risk social risk factor (Q1 vs Q4 OR = 2.27, 95% CI = 2.19-2.37), but rurality was not (OR = 1.02, 95% CI = 0.97-1.07) after adjusting for HOUSES. Conclusions: The increased prevalence of social risk factors among rural residents is largely explained by individual SES measured by HOUSES Index.
Genetic risk factors modulate the association between physical activity and colorectal cancer
Kim, Andre E., Fu, Yubo, Morrison, John, Lin, Yi, Berndt, Sonja, Chang-Claude, Jenny, Conti, David V., Corley, Douglas A. , Gruber, Stephen B. , Harlid, Sophia , Huyghe, Jeroen R. , Kundaje, Anshul , Martín, Vicente , Newton, Christina C. , Hardikar, Sheetal , Pai, Rish K. , Papadimitriou, Nikos , Pinchev, Mila, Schoen, Robert , Tsilidis, Konstantinos K, Duijnhoven, Franzel J. B. van, Visvanathan, Kala , Wolk, Alicja, Woods, Michael O. , Wu, Anna H. , Ulrich, Cornelia M. , Peters, Ulrike, Gauderman, W. James, Moreno, Victor, Martín, Vicente , Drew, David A. , Martín, Vicente , Drew, David A , Visvanathan, Kala , Kundaje, Anshul , Papadimitriou, Nikos , Peoples, Anita R , Obón‐Santacana, Mireia , Kawaguchi, Eric , Qu, Conghui , Moratalla-Navarro, Ferrán , Morrison, John, Arndt, Volker , Bien, Stephanie A. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Chang‐Claude, Jenny , Conti, David V. , Devall, Matthew A M , Dimou, Niki , Gunter, Marc J. , Harrison, Tabitha A. , Hoffmeister, Michael , Hsu, Li , Keku, Temitope O , Lewinger, Juan Pablo , Lynch, Brigid M , Marchand, Loı̈c Le , Murphy, Neil , Ogino, Shuji , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Platz, Elizabeth A. , Potter, John D. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C. , Schoen, Robert E., Shcherbina, Anna, Stern, Mariana Carla , Su, Yu-Ru , Thomas, Claire E. , Tian, Yu , Tsilidis, Konstantinos K. , Um, Caroline Y. , Guelpen, Bethany Van , Wang, Jun, White, Emily , Wolk, Alicja , Peters, Ulrike, Gauderman, W. James

Mayo Clinic

No container title available | September 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7350654/v1 | PMID 40951278 Get It

Abstract Background Physical activity (PA) is an established protective factor for colorectal cancer (CRC), but it is unclear if genetic variants modify this effect. To investigate this possibility, we conducted a genome-wide gene–PA interaction analysis. Methods Using logistic regression and two-step and joint tests, we analyzed interactions between common genetic variants across the genome and PA in relation to CRC risk. Self-reported PA levels were categorized as active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk) and as study- and sex-specific quartiles of activity. Results PA had an overall protective effect on CRC (OR [active vs. inactive] = 0.85; 95%CI = 0.81–0.90). The two-step GxE method identified an interaction between rs4779584, an intergenic variant near the GREM1 and SCG5 genes, and PA for CRC risk (p-interaction = 2.6×10 − 8 ). Stratification by genotype at this locus showed a significant reduction in CRC risk by 20% in active vs. inactive participants with the CC genotype (OR = 0.80; 95%CI = 0.75–0.85), but no significant PA–CRC association among CT or TT carriers. When PA was modeled as quartiles, the 1-d.f. GxE test identified that rs56906466, an intergenic variant near the KCNG1 gene, modified the association between PA and CRC (p-interaction = 3.5×10 − 8 ). Stratification at this locus showed that increase in PA (highest vs. lowest quartile) was associated with a lower CRC risk solely among TT carriers (OR = 0.77; 95%CI = 0.72–0.82). Conclusions In summary, we identified two genetic variants that modified the association between PA and CRC risk. One of them, related to GREM1 and SCG5 , suggests that the bone morphogenetic protein (BMP)-related, inflammatory, and/or insulin signaling pathways may be associated with the protective influence of PA on colorectal carcinogenesis.
Repeat-associated ataxias in a German patient cohort analysed by targeted parallel long-read sequencing
Erdmann, Hannes , Schaub, Annalisa , Lucas, Morghan C. , Scholz, Veronika , Benet‐Pagès, Anna , Dineiger, Christine, Mayer, Veronika, Buren, Inga Van , Breithausen, Eva, Akbari, Karl, Sauer, Mayra , Krakowsky, Rosanna , Schnabel, Franziska , Dunker, Konstanze, Fabritius, Lena, Gerb, Johannes , Grabova, Denis , Möhwald, Ken , Näher, Marius, Steinmetz, Karoline , Thiessen, Franziska, Jäck, Alexander , Schreyer, Isolde, Mämecke, Larissa, Wilfling, Sibylle, Wunderlich, Gilbert , Hellenbroich, Yorck, Muhle, Kirsten, Claus, Inga, Klopstock, Thomas, Strupp, Michael, Xiong, Chengjie , Huppert, Doreen , Becker‐Bense, Sandra , Filippopulos, Filipp , Kilpert, Fabian , Kaya, Sabine, Schöberl, Florian, Neuhann, Teresa , Holinski‐Feder, Elke , Zwergal, Andreas , Abicht, Angela, Cordts, Isabell , Gerb, Johannes , Brenner, David , Xiong, Chengjie , Kilpert, Fabian , Depienne, Christel , Zwergal, Andreas , Becker, Kerstin , Mayer, Veronika, Akbari, Karl, Schneider, Christine B. , Thiessen, Franziska, Schneider-Gold, Christiane , Zittel, Simone , Petersen, Christina, Huchtemann, Tessa , Höglinger, Günter U. , Leitão, Elsa , Depienne, Christel , Abicht, Angela

Mayo Clinic

Brain | September 1, 2025 | Volume: 149 | Issue: 3 | Pages: 993-1006

10.1093/brain/awaf318 | PMID 40898875 Get It

Abstract Hereditary adult-onset ataxias are a heterogeneous group of phenotypically overlapping conditions, often caused by pathogenic expansions of short tandem repeats. Currently, 18 repeat disorders with a core phenotype of adult-onset ataxia are known. Diagnosis typically relies on sequential PCR-based methods, which are labour-intensive and lack precision. Long-read sequencing (LRS) has the potential to overcome these limitations and is currently implemented and validated in clinical genetics. Using clinical nanopore Cas9-targeted sequencing (Clin-CATS) for parallel in-depth repeat analysis, we evaluated a diagnostic cohort of 513 adult-onset ataxia patients, determining frequencies of all known repeat-associated ataxias except Spinocerebellar ataxia 4 (SCA4), as well as the carrier frequencies for autosomal-recessive disorders, RFC1 spectrum disorder and Friedreich’s ataxia (FRDA). Additionally, phenotypes of patients with established genetic diagnoses were characterized, especially those of patients living with RFC1 spectrum disorder and SCA27B. Repeat-associated ataxias were confirmed in 33.3% of cases, including rare ataxias, such as SCA10, SCA36 and SCA37, alongside as the most prevalent conditions SCA27B and RFC1 spectrum disorder. Potentially pathogenic expansions in FGF14 were identified in an additional 4.7% of patients. Testing of another 347 patients for ZFHX3 expansions linked to SCA4 did not identify any cases. Dual diagnoses were frequent, occurring in 6.4% of patients with repeat-associated ataxia. We confirmed a high RFC1 spectrum disorder carrier frequency (7.2%) and reclassified certain FXN expansions as likely non-pathogenic, resulting in a lower than estimated carrier frequency for FRDA of 0.8%. We also identified novel repeat configurations in several loci and illustrated the high heterogeneity of repeat expansions in RFC1, highlighting it as a potential source of false results when using PCR-based methods. This study underscores the diagnostic advantages of LRS for comprehensive repeat analysis and recommends its adoption as a standard in clinical genetics, replacing Southern blot and PCR-based approaches. Furthermore, based on our findings in a large patient cohort a re-evaluation of existing phenotype-genotype correlations is recommended as well as evaluating additional parameters alongside the repeat length to improve diagnostic precision of repeat analysis.
Left Ventricular Ejection Fraction and Benefit of Tricuspid Valve Interventions – Insights from the International TRIGISTRY
Dannenberg, Varius , Topilsky, Yan , Benfari, Giovanni , Weber, Marcel, Eixerés‐Esteve, Andrea , Bazire, Baptiste , Iung, Bernard , Riant, Elisabeth , Habib, G., Hausleiter, Jörg , Stolz, Lukas , Badano, Luigi P. , Tourneau, Thierry Le, Zamorano, José Luis , Fam, Neil , Sievert, Horst, Heuts, Samuel , Nejjari, Mohammed, Bonis, Michele De , Rudolph, Volker , Lurz, Philipp, Bax, Jeroen J., Gauda, Roja, Bernick, Jordan , Wells, George A. , Maisano, Francesco, Bartko, Philipp E. , Investigators, for the TRIGISTRY, Messika-Zeitoun, David , Enriquez-Sarano, Maurice , Benfari, Giovanni , Hausleiter, Jörg , De Bonis, Michele , Heitzinger, Gregor , Dreyfus, Julien , Marsan, Nina Ajmone , Taramasso, Maurizio , Russo, Giulio , Bohbot, Yohann , Iliadis, Christos , Weber, Marcel , Nombela‐Franco, Luis , Obadia, Jean‐François , Estévez‐Loureiro, Rodrigo , Donal, Erwan , Lavie-Badie, Yoan , Tourneau, Thierry Le, Coisne, Augustin , Modine, Thomas , Praz, Fabien , von Bardeleben, Ralph Stephan , Hahn, Rebecca T , Muraru, Denisa , Adamo, Marianna , Nejjari, Mohammed , Chan, Vincent, Carnero, Manuel , Crestanello, Juan A. , Maisano, Francesco , Enriquez‐Sarano, Maurice , Messika–Zeitoun, David , Investigators, for the TRIGISTRY

Mayo Clinic

European Journal of Heart Failure | August 31, 2025 | Volume: 27 | Issue: 11 | Pages: 2634-2643

10.1002/ejhf.3797 | PMID 40886066 Get It

ABSTRACT Aims The impact of treatment for tricuspid regurgitation (TR) across different levels of left ventricular ejection fraction (LVEF) remains uncertain. This study aimed to compare the outcomes of surgical and transcatheter tricuspid valve interventions (TTVI) to conservative (medical) management across LVEF categories. Methods and results Patients with severe isolated TR from the TRIGISTRY, a multicentre international registry, were categorized based on LVEF (preserved ejection fraction [pEF]: ≥50%, mildly reduced ejection fraction [mrEF]: 41–49%, and reduced ejection fraction [rEF]: ≤40%). We assessed the impact of treatment modality and procedural success (mild-to-moderate or lower residual TR) on 2-year survival within each LVEF category. Among 2384 patients, 1383 had pEF, 400 had mrEF, and 601 had rEF. Compared to conservative management, surgery (p &lt; 0.0005) and TTVI (p &lt; 0.0001) were associated with a survival benefit in patients with pEF. No significant survival advantage was observed in patients with mrEF (p = 0.28 for both), nor in those with rEF (p = 0.76 and p = 0.22, respectively). Similar results were obtained when surgical and transcatheter interventions were grouped (p &lt; 0.0001, p = 0.17 and p = 0.29 in patients with pEF, mrEF and rEF, respectively). Patients with residual TR after TTVI exhibited a trend toward worse survival compared to those managed conservatively across all LVEF categories (p = 0.47, p = 0.33 and p = 0.008 in pEF, mrEF and rEF, respectively). Conclusions Transcatheter tricuspid valve intervention, whether surgical or transcatheter-based, was associated with improved survival in patients with pEF but not in those with mrEF or rEF. Residual TR remained a significant prognostic factor across the entire LVEF spectrum. These findings highlight the need for careful patient selection when considering TTVI in individuals with rEF.
Topic: Esophagus neoplasia (Barrett’s, Cancer)Abstract ID: 98Paraconduit Hernia After Esophagectomy: Associated Risk Factors and Surgical Management
Cornejo, Jorge , Tsenteradze, Tamar , Bowers, Steven P. , Elli, Enrique F. , Cornejo, Jorge , Pontecorvo, Agustina A. , Thomas, Mathew

Mayo Clinic

Foregut: The Journal of the American Foregut Society | August 30, 2025 | Volume: 5 | Issue: 3 | Pages: 348-348

10.1177/26345161251371455 Get It

Topic: Esophagus benign - gerd, achalasia, motilityAbstract ID: 111Enucleation of Esophageal Leiomyoma: Should Fundoplication Be Performed When the Tumor Is Located at the Esophagogastric Junction?
Agustina, Pontecorvo, Cornejo, Jorge , Tsenteradze, Tamar , Thomas, Mathew , Bowers, Steven P. , Elli, Enrique F. , Cornejo, Jorge

Mayo Clinic

Foregut: The Journal of the American Foregut Society | August 30, 2025 | Volume: 5 | Issue: 3 | Pages: 357-357

10.1177/26345161251371908 Get It

Pleuroparenchymal fibroelastosis: review of 81 cases
Baqir, Misbah , Hartman, Thomas E. , Yi, Eunhee E., Ryu, Jay H. , Farah, Wigdan H, Ryu, Jay H , LeMahieu, Allison , Farah, Wigdan

Mayo Clinic

Expert Review of Respiratory Medicine | August 29, 2025 | Volume: 20 | Issue: 2 | Pages: 217-226

10.1080/17476348.2025.2555079 | PMID 40879600 Get It

Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes
Tawfiq, R., Spears, Grant M. , Young, Jason R., Mahowald, Madeline , Tobin, W. Oliver , Patgunarajah, Ubenthira, Ruan, Gordon , Yi, Dongni , Zanwar, Saurabh , Gruber, Lucinda , Ravindran, Aishwarya , Sartori‐Valinotti, Julio C. , Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Dasari, Surendra , Abeykoon, Jithma P. , Tawfiq, Reema K , Mahowald, Madeline K , Ruan, Gordon J , Acosta-Medina, Aldo A , Ravindran, Aishwarya , Shah, Mithun V , Bennani, N Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Sartori-Valinotti, J C , Vassallo, Robert , Ryu, Jay H , Witzig, T.E. , Goyal, Guarav , Abeykoon, Jithma P , Tobin, W Oliver , Rech, Karen L. , Koster, Matthew J. , Acosta‐Medina, Aldo A. , Shah, Meera , Bennani, N. Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Witzig, Thomas E. , Go, Ronald S. , Goyal, Gaurav

Mayo Clinic

Blood Advances | August 28, 2025 | Volume: 9 | Issue: 23 | Pages: 5988-6000

10.1182/bloodadvances.2025016608 | PMID 40875593 Get It

Abstract Erdheim-Chester disease (ECD) is a rare systemic histiocytic neoplasm, with cardiac morbidities, including cardiovascular (CV) risk factors and cardiac conditions, playing a significant yet poorly understood role in the disease burden. This study evaluated the prevalence, characteristics, and prognosis of ECD in patients with (ECD-C) and without cardiac involvement (ECD-noC) and compared the burden of cardiac morbidities with matched controls. Patients diagnosed with ECD between 1990 and 2021 at a tertiary center were included, with cardiac involvement centrally assessed using radiographic studies. Cardiac morbidities were compared with a control group without ECD, matched for age, sex, body mass index, and smoking history. Among 104 patients with ECD, 39 (37%) had cardiac involvement. Patients with ECD-C had higher rates of hypertension (67% vs 46%), hyperlipidemia (67% vs 40%), heart failure (36% vs 8%), and pericardial effusion (28% vs 2%) than those with ECD-noC. Compared with the matched non-ECD cohort, patients with ECD had higher prevalence of coronary artery disease (20% vs 7%), heart failure (18% vs 4%), and antihypertensive drug use (55% vs 40%). Notably, patients with ECD-C had inferior progression-free survival (PFS) from frontline therapy compared with patients with ECD-noC (5-year PFS, 28.3% vs 70.5%). These findings highlight the burden of CV risk factors and cardiac conditions in ECD, even without a clinical diagnosis of ECD-C. Importantly, this cardiac morbidity burden is substantial for patients with ECD-C compared with ECD-noC. Our findings highlight the need for comprehensive cardiac risk assessment and management strategies to improve patient outcomes.
Endovascular Treatment of Brain Arteriovenous Malformations After New Liquid Embolic Agents: A Single-Center 7-Year Experience With Safety Outcomes
Souza, Natália Vasconcellos de Oliveira , Cortese, Jonathan , Soize, Sébastien , Chalumeau, Vanessa , Mihalea, Cristian , Rodriguez‐Erazú, Fernanda , Caroff, Jildaz , Vieira, Maria JoséFemenias , Ikka, Léon , Spelle, Laurent , de Oliveira Souza, Natália Vasconcellos , Vieira, Mathieu , Spelle, Laurent , Mihalea, Cristian , Chalumeau, Vanessa , Cortese, Jonathan

Mayo Clinic

Neurosurgery | August 28, 2025 | Volume: 98 | Issue: 5 | Pages: 1063-1075

10.1227/neu.0000000000003691 | PMID 40874751 Get It

BACKGROUND AND OBJECTIVES: Embolization is part of multidisciplinary brain arteriovenous malformations (AVMs) treatment, yet safety data for novel liquid embolization agents (LEAs) such as Squid and PHIL remain limited. This study reports complications and outcomes from curative embolization using Onyx, Squid, PHIL, and Glue. METHODS: Adult patients with brain AVMs treated with LEAs from July 2015 to December 2022 were reviewed for intraprocedural technical issues, postoperative hemorrhagic, and ischemic complications. Minor (modified Rankin Scale ≤2) and major complication rate (morbidity/modified Rankin Scale >2), mortality, and 6-month angiographic cure rate were evaluated. RESULTS: In total, 135 patients (62.2% male, mean age 41.7 ± 15.1 years) with 206 embolizations (34% Onyx, 18.9% Squid, 17.5% PHIL, 28.2% Glue) were included. Overall, 87.4% procedures were in ruptured AVMs and 84% treated by the transarterial technique (84%). The 6-month angiographic cure rate was 53.3%, higher when nonadhesive LEAs were used than Glue (65.3% vs 17.6%, P < .001). In adjusted analysis, only eloquent location (odds ratio [OR] = 4.4; P = .007) and Glue (OR = 9.1; 95% CI 2.9-28.9, P < .001) were predictors of lower angiographic occlusion rate, whereas size had an inverse correlation (OR = 0.67; P = .019). Technical procedural complications, hemorrhagic, and ischemic rates were 10.2% (2.2% morbidity), 13.1% (3.7% morbidity and 2.2% mortality), and 9.2% (2.2% morbidity, 0% mortality), respectively, regardless of the preferred LEA. Minor, major complications, and mortality rates were 3.7%, 4.4%, and 2.2%, respectively. Hemorrhage was the major contributor to morbidity and mortality, whereas deep venous drainage was an independent predictor of hemorrhage and mortality. CONCLUSION: PHIL and Squid demonstrated complication and angiographic cure rates comparable with Onyx. However, curative embolization of brain AVMs resulted in only moderate angiographic occlusion. Larger multicenter studies with standardized operator protocols, cost-effectiveness assessments, and extended follow-up are warranted to validate these findings.